Reynolds Holding is a Breakingviews columnist who writes from New York about the law in conjunction with Reuters Legal. Before joining Breakingviews, he was a national editorial producer for the Law & Justice Unit at ABC News, a senior writer for Time magazine and the executive editor of Legal Affairs, the first general interest magazine about the law. He spent more than a decade as an investigative reporter and columnist for The San Francisco Chronicle, where he was named a Pulitzer Prize finalist for explanatory writing. Before becoming a journalist, he practiced corporate law at the New York firm of Debevoise & Plimpton. He graduated from Harvard College and Duke University School of Law.
- Tel: +1 646 223 8420
- E-mail: firstname.lastname@example.org
The U.S. justices allowed antitrust suits against pharmaceutical firms like Solvay that pay rivals not to offer cheaper generic medicines. The practice might still pass muster, but the anticompetitive effects are clear. Drug makers may end up charging consumers less.
The Supreme Court ruled that companies can hold exclusive rights to synthetic human genes, but not naturally occurring ones. That allows biotech businesses to reap rewards for their work without stifling the research of others. The decision serves science, industry and the law.
The CEO’s offer to take the produce purveyor private requires approval from independent directors and minority shareholders. These low-hanging provisions ensure a degree of fairness in such deals. The extra legal protection just afforded by a Delaware judge is the cherry on top.
- Surveillance state put on timely legal notice
- Apple takes smart but needed gamble in e-book spat
- Apple patent case exposes trade arbiter's flaws
- Bribery law bogeyman scares up new legal clients
- Wall Street could use some court consistency
- Investors won't want to hear latest on free speech
- U.S. flops at collecting fines and paying them out